Promethera’s mission is to apply its proprietary liver cell-based technology and complimentary biological technologies to meet the needs of patients with acute and chronic liver diseases.
Promethera is pioneering the development of novel cell-based therapies for the treatment of a broad variety of liver diseases. The Company’s platform has the potential to deliver novel therapeutic options for inherited disorders including hemophilia as well as acquired chronic and acute liver diseases such as Acute-on-Chronic-Liver Failure (ACLF), fibrosis and Non-Alcoholic Steatohepatits (NASH).
Promethera’s most advanced cell-based therapy, HepaStem, is currently being evaluated in an open-label Phase 2a clinical trial to treat patients with Acute-on-Chronic-Liver Failure (ACLF). The program has the potential to target more prevalent chronic or progressive severe liver diseases such as Non-Alcoholic Steatohepatitis (NASH) and Fibrosis. Promethera has further strengthened its pipeline with complementary biologics, including the anti-TNF-R1 antibody Atrosimab.
Promethera Biosciences is headquartered in Belgium's Walloon region, which is internationally known for excellence in cell therapy research. From here, the company has begun early on to establish a global footprint with a US subsidiary in Durham, North Carolina, a biologics unit in Basel, Switzerland and a Japanese branch office in Tokyo. Each site serves a specific function within the Promethera Group structure.
Get a brief overview of Promethera's activities and view our latest corporate presentation.
Since inception, Promethera Biosciences has raised EUR 58 million in equity and semi-equity from a broad range of leading European and Asian investors.
Promethera has outstanding capabilities and expertise in liver biology and cell-based medicine. These activities currently include the use of HepaStem in hemophilia and the Heparesc product line. More